430 E 29th St Fl 14
New York, New York 10016-8367
Phone: 12125464000
www.bms.com
Healthcare giant Bristol-Myers Squibb ($BMY) looks like the perfect place to wait out the extreme volatility that has hit the market this summer. T…
NEW YORK CITY (dpa-AFX) - Germany-headquartered drug manufacturer Evotec SE (EVT, EVO) on Thursday announced progress in the company''s strategic partnership with U.S.-based drug manufacturer Brist…
Key scientific achievement advances the joint neuroscience pipeline and earns a payment of US$ 25 m to Evotec to progress further research HAMBURG, GERMANY / ACCESSWIRE / August 8, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: … Jetzt den vollständigen Artikel lesen
Evotec''s neuroscience partnership with Bristol Myers Squibb advances, securing $25M payment. Discover how this collaboration is driving innovative treatments for neurodegenerative diseases and shaping the future of medicine.
FDA issues untitled letter to Bristol Myers Squibb over misleading claims on cancer drug website for cancer drug Krazati. Read more here.
Following regulatory approval in the earlier line setting this quarter, Abecma generated $54 million U.S. commercial revenue and saw meaningful growth in demand Recent completion of Hemophilia A and gene editing technology sale to Novo Nordisk for up to $40 million reinforces exclusive focus on Abecma with streamlined cost structure Approximately $28 million (43%) quarter-on-quarter reduction in operating expenses due to completion of sale of R&D business to Regeneron on April 1, 2024 Ended quarter with approximately $202 million cash, cash equivalents, and marketable securities; cash runway beyond 2027 Conference call today at 8:00 AM ET 2seventy bio, Inc. (NASDAQ: TSVT ), today reported financial results and recent highlights for the second quarter ended June 30, 2024. "This year has been transformative for 2seventy, and we enter the second half in a strong financial and operational position, poised for commercial growth," said Chip Baird, CEO. "We dramatically reduced our cost structure and strengthened our balance sheet with the completion of the sale of our oncology R&D business to Regeneron and the sale of our Hemophilia A program and gene editing technology to Novo Nordisk.
Bristol-Myers Squibb''s upgraded guidance is too small to improve prospects for H2 2024. Read more to see why I’m downgrading BMY stock to Sell.
No summary available.